Table of Contents
September 24, 2026
2 min read
Key takeaways:
Onswik was approved to control glucose levels along with diet and exercise for adults with type 2 diabetes.
The therapy is the second once-weekly basal insulin approved by the FDA for type 2 diabetes.
The FDA has approved a once-weekly basal insulin to control glucose levels for adults with type 2 diabetes, Eli Lilly announced.
Insulin efsitora alfa-gobe (Onswik, Lilly) is a therapy that can deliver steady levels of basal insulin to adults with type 2 diabetes for 7 days. The FDA approved insulin efsitora alfa-gobe for use alongside diet and exercise to help maintain glycemic control.
The FDA approved insulin efsitora alfa-gobe as the second once-weekly basal insulin for adults with type 2 diabetes.
The therapy was granted FDA approval based on data from four phase 3 studies in the QWINT trial program. As Healio previously reported, the QWINT-1 trial found insulin efsitora alfa-gobe was noninferior to daily 100 U insulin glargine for change in HbA1c among adults with type 2 diabetes who were using insulin for the first time. In the QWINT-3 trial, adults receiving insulin efsitora alfa-gobe had a greater decrease in HbA1c at 1 year than those receiving 100 U insulin degludec (Novo Nordisk) among those with type 2 diabetes using basal insulin and up to three glucose-lowering medications at the start of the trial. The QWINT-4 trial found insulin efsitora alfa-gobe conferred a noninferior HbA1c reduction compared with insulin glargine among adults with type 2 diabetes previously treated with basal insulin who received at least two prandial insulin injections per day at baseline. In the QWINT-2 trial, adults with type 2 diabetes who did not previously use insulin and were using up to three glucose-lowering drugs at baseline had a noninferior HbA1c change with insulin efsitora alfa-gobe compared with insulin degludec.
In all four trials, the safety profile for insulin efsitora alfa-gobe was similar to insulin glargine and insulin degludec. Insulin efsitora alfa-gobe is not approved for adults with type 1 diabetes and should not be used in that population due to increased risk for severe hypoglycemia, according to the press release.
Insulin efsitora alfa-gobe is the second once-weekly basal insulin approved by the FDA for adults with type 2 diabetes. As Healio previously reported, the FDA approved insulin icodec-abae (Awiqli, Novo) in March as the first weekly basal insulin for adults with type 2 diabetes.
“For over a century, Lilly has been developing insulins that transformed diabetes care for millions of people worldwide, but delays in initiating treatment and the burden of daily injections can have a real impact on patients’ day-to-day experience managing type 2 diabetes,” Kenneth Custer, PhD, executive vice president and president of Lilly Cardiometabolic Health, said in a press release. “Onswik offers a new once-weekly basal insulin option for patients and reflects our continued commitment to deliver innovative treatment options that expand choice and provide greater flexibility in how people manage type 2 diabetes.”
Lilly stated in the press release that the Onswik KwikPen will be available in the U.S. in the coming months in 500 U/mL and 1,000 U/mL doses.